High Purity Pidotimod(PGT/1A) CAS 121808-62-6

Basic Info

Model No.: 121808-62-6

Function: Nutritional Therapeutics

Grade Standard: Medicine Grade

State: Solid

Volatile: Not Volatile

Additional Info

Packaging: AS REQUIRED

Productivity: KGS

Brand: VOLSENCHEM

Transportation: Air

Place of Origin: CHINA

Supply Ability: TRUE MANUFACTURER

Certificate: ISO

Product Description

Pidotimod CAS NO 121808-62-6 is a synthetic dipeptide with immunological modulatory activity on both the adaptive and innate immune responses. In clinical, Pidotimod 121808-62-6 always apply to treat acute respiratory tract infections and stimulates both cellular and humoral immunity. Pidotimod 121808-62-6, supplied by us, is white crystalline powder with the purity more than 99.3%. And the basic information about Pidotimod CAS 121808-62-6 as followed: the melting point is 194-196℃; PH is 2.5; the loss on drying is less than 0.14%; and the single impurities and total impurity is less than 0.35% and 0.69% respectively. 

Thera. Category: Anti immunostimulant

Cas No.: 121808-62-6

Synonym : (r-(r*,s*))-3-((5-oxo-2-pyrrolidinyl)carbonyl)-4-thiazolidinecarboxylicacid;(r)-3-((s)-(5-oxo-2-pyrrolidinyl)carbonyl)-thiazolidin-4-carbonsaeure;4-thiazolidinecarboxylicacid,3-((5-oxo-2-pyrrolidinyl)carbonyl)-,(r-(r*,s*));pgt/1a;(R)-3-[(S)-(5-OXO-2-PYRROLIDINYL)CARBOXYL]-THIAZOLIDINE-4-CARBOCYLIC ACID;PIDOTIMOD;(4r)-3-[[(2s)-5-oxo-2-pyrrolidinyl]carbonyl]-4-thiazolidinecarboxylic acid;3-(5-OXO-2-PYRROLIDINYL)CARBONYL-4-THIAZOLIDINECARBOXYLICACID

Molecular Weight: 244.27

Molecular formula: C9H12N2O4S

Assay: ≥98.%

Appearance: Yellow-Orange Crystalline Solid

Packing:Export worthy packing

Material Safety Data Sheet:Available on request

Usage:Pidotimod CAS 121808-62-6 is a synthetic dipeptide with immunological modulatory activity on both the adaptive and innate immune responses. This compound has been shown to induce dendritic cell maturation and up-regulate the expression of HLA-DR and co-stimulatory molecules CD83 and CD86, which are integral to communication with adaptive immunity cells. Pidotimod has also been shown to stimulate dendritic cells to release pro-inflammatory molecules such as MCP-1 and TNF-α cytokines, and to inhibit thymocyte apoptosis caused by a variety of apoptosis inducing molecules.